{"id":240421,"date":"2018-07-12T06:56:03","date_gmt":"2018-07-12T06:56:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=240421"},"modified":"2018-07-12T06:56:03","modified_gmt":"2018-07-12T06:56:03","slug":"global-anticd152-antibody-market-2018-industry-analysis-share-growth-sales-trends-supply-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-anticd152-antibody-market-2018-industry-analysis-share-growth-sales-trends-supply-forecast_240421.html","title":{"rendered":"Global ANTI-CD152 ANTIBODY Market 2018 Industry Analysis, Share, Growth, Sales, Trends, Supply, Forecast."},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“\\”ANTI-CD152 ANTIBODY Market\\””<\/div>\n<\/div>\n<\/div>\n
WiseGuyReports.com adds \u201cANTI-CD152 ANTIBODY Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2025\u201d reports to its database.<\/div>\n

ANTI-CD152 ANTIBODY Market<\/a><\/strong>:<\/strong><\/p>\n

Executive Summary<\/strong><\/p>\n

The comprehensive list of Anti-CD152 Antibody that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of Anti-CD152 Antibody pipeline products that are in Phase 3, Phase 2, Phase 1, preclinical and discovery across different indications. This report also provides comprehensive research on the companies that are working on Anti-CD152 Antibody including the deals and acquisitions.<\/p>\n

Report Coverage: <\/strong><\/p>\n

Clinical (Phase Products)<\/p>\n

Non-clinical (Preclinical and Discovery)<\/p>\n

Dormant and Discontinued<\/p>\n

Companies Mentioned<\/strong><\/p>\n

ImmunOs Therapeutics AG, Bioinvent International, Tikcro Technologies, Nativis, Agenus, MacroGenics, Ultimovacs AS<\/p>\n

Request Sample Report @ https:\/\/www.wiseguyreports.com\/sample-request\/3271727-anti-cd152-antibody-pipeline-analysis-2018<\/a><\/strong><\/p>\n

Table of Content:<\/strong><\/p>\n

Executive Summary 
Overview of Anti-CD152 antibodies 
Recent Trends 
Pipeline Therapeutics 
Therapeutics under Development by Companies 
Late State Products 
· Product Description 
· Research and Development 
· Product Development Activities<\/p>\n

Mid Stage Products<\/strong> 
· Product Description 
· Research and Development 
· Product Development Activities<\/p>\n

Early Stage Products<\/strong> 
· Product Description 
· Research and Development 
· Product Development Activities<\/p>\n

Therapeutic Assessment<\/strong> 
· Assessment by Route of Administration 
· Assessment by Phase & Route of Administration 
· Assessment by Molecule Type 
· Assessment by Phase & Molecule type 
Collaborations and Acquisitions Details 
Dormant Products 
Discontinued Products 
Appendix 
Methodology 
About Adroit healthcare services <\/p>\n

Disclaimer 
Table 1: Products Under Development for anti-CD152 antibodies, 2018 
Table 2: Products under Development by Companies, 2018 
Table 3: Late Stage Products, 2018 
Table 4: Mid Stage Products, 2018 
Table 5: Early Stage Products, 2018 
Table 6: Pre-Clinical and Discovery Products, 2018 
Table 7: Assessment by Route of Administration, 2018 
Table 8: Assessment by Stage and Route of Administration, 2018 
Table 9: Assessment by Molecule Type, 2018 
Table 10: Assessment by Stage and Molecule Type, 2018 
Table 11: Comparative Analysis 
Table 12: Dormant Products 
Table 13: Discontinued Products 
Figure 1: Products Under Development for anti-CD152 antibodies, 2018 
Figure 2: Products under Development by Companies, 2018 
Figure 3: Late Stage Products, 2018 
Figure 4: Mid Stage Products, 2018 
Figure 5: Early Stage Products, 2018 
Figure 6: Pre-Clinical and Discovery Products, 2018 
Figure 7: Assessment by Route of Administration, 2018 
Figure 8: Assessment by Stage and Route of Administration, 2018 
Figure 9: Assessment by Molecule Type, 2018 
Figure 10: Assessment by Stage and Molecule Type, 2018 
Figure 11: Comparative Analysis 
Figure 12: Dormant Products 
Figure 13: Discontinued Products<\/p>\n

Continuous…<\/strong><\/p>\n

For further information on this report, visit –<\/strong> https:\/\/www.wiseguyreports.com\/reports\/3271727-anti-cd152-antibody-pipeline-analysis-2018<\/a><\/strong><\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“\\”ANTI-CD152 ANTIBODY Market\\”” WiseGuyReports.com adds \u201cANTI-CD152 ANTIBODY Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2025\u201d reports to its database. ANTI-CD152 ANTIBODY Market: Executive Summary The comprehensive list of Anti-CD152 Antibody that are marketed for different … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-240421","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/240421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=240421"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/240421\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=240421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=240421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=240421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}